Return on investment (ROI) calculations are common tools used by pharmaceutical and biotechnology companies in evaluating product returns, guiding decisions on further product development or terminating programs prior to company losses. ROI calculations compare the estimated profits from a product to the investments necessary to get the product developed, approved and marketed. Risk factors are incorporated into the ROI, which consider multiple factors including competitor products and market demand. ROI calculations enables a company to set and apply metrics for the evaluation of projects that can be applied consistently, across a portfolio, and goes beyond simple profitability assessments. When coupled with additional financial tools and strategic evaluations such as strengths, weaknesses, opportunities and threats (SWOT) analysis, ROI can provide invaluable and comparable insight into the value of potential projects and products. Here, we present a framework for executing ROI calculations to enable investment or termination decisions for research and development projects. This is augmented with insight on how to apply the framework to academic, government and NGO evaluations where ‘profits’ are not always measured in purely economic terms. Implementing ROI in the evaluation process facilitates go/no go decisions and the comparison of projects using a simple, consistent financial approach.
Read full abstract